These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

564 related articles for article (PubMed ID: 35790854)

  • 1. Targeting telomeres: advances in telomere maintenance mechanism-specific cancer therapies.
    Gao J; Pickett HA
    Nat Rev Cancer; 2022 Sep; 22(9):515-532. PubMed ID: 35790854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Telomere maintenance mechanisms in cancer: telomerase, ALT or lack thereof.
    Claude E; Decottignies A
    Curr Opin Genet Dev; 2020 Feb; 60():1-8. PubMed ID: 32114293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ALT: A Multi-Faceted Phenomenon.
    Sommer A; Royle NJ
    Genes (Basel); 2020 Jan; 11(2):. PubMed ID: 32012790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pan-cancer analysis of telomere maintenance mechanisms.
    Hakobyan M; Binder H; Arakelyan A
    J Biol Chem; 2024 Jun; 300(6):107392. PubMed ID: 38763334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Telomere Length Maintenance in Cancer: At the Crossroad between Telomerase and Alternative Lengthening of Telomeres (ALT).
    De Vitis M; Berardinelli F; Sgura A
    Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29463031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alternative Lengthening of Telomeres: DNA Repair Pathways Converge.
    Sobinoff AP; Pickett HA
    Trends Genet; 2017 Dec; 33(12):921-932. PubMed ID: 28969871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer-associated SMARCAL1 loss-of-function mutations promote alternative lengthening of telomeres and tumorigenesis in telomerase-negative glioblastoma cells.
    Liu H; Xu C; Diplas BH; Brown A; Strickland LM; Yao H; Ling J; McLendon RE; Keir ST; Ashley DM; He Y; Waitkus MS
    Neuro Oncol; 2023 Sep; 25(9):1563-1575. PubMed ID: 36689342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How Do Telomere Abnormalities Regulate the Biology of Neuroblastoma?
    Akter J; Kamijo T
    Biomolecules; 2021 Jul; 11(8):. PubMed ID: 34439779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histone demethylase KDM2A is a selective vulnerability of cancers relying on alternative telomere maintenance.
    Li F; Wang Y; Hwang I; Jang JY; Xu L; Deng Z; Yu EY; Cai Y; Wu C; Han Z; Huang YH; Huang X; Zhang L; Yao J; Lue NF; Lieberman PM; Ying H; Paik J; Zheng H
    Nat Commun; 2023 Mar; 14(1):1756. PubMed ID: 36991019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SLX4IP N-terminus dictates telomeric localization in ALT-like castration-resistant prostate cancer cell lines.
    Mangosh TL; Grabowska MM; Taylor DJ
    Prostate; 2021 Nov; 81(15):1235-1251. PubMed ID: 34492133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alternative mechanisms of telomere lengthening: permissive mutations, DNA repair proteins and tumorigenic progression.
    Gocha ARS; Harris J; Groden J
    Mutat Res; 2013; 743-744():142-150. PubMed ID: 23219603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The telomere maintenance mechanism spectrum and its dynamics in gliomas.
    Kim S; Chowdhury T; Yu HJ; Kahng JY; Lee CE; Choi SA; Kim KM; Kang H; Lee JH; Lee ST; Won JK; Kim KH; Kim MS; Lee JY; Kim JW; Kim YH; Kim TM; Choi SH; Phi JH; Shin YK; Ku JL; Lee S; Yun H; Lee H; Kim D; Kim K; Hur JK; Park SH; Kim SK; Park CK
    Genome Med; 2022 Aug; 14(1):88. PubMed ID: 35953846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alternative Lengthening of Telomeres (ALT) in Tumors and Pluripotent Stem Cells.
    Zhao S; Wang F; Liu L
    Genes (Basel); 2019 Dec; 10(12):. PubMed ID: 31835618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA methylation mediated up-regulation of TERRA non-coding RNA is coincident with elongated telomeres in the human placenta.
    Novakovic B; Napier CE; Vryer R; Dimitriadis E; Manuelpillai U; Sharkey A; Craig JM; Reddel RR; Saffery R
    Mol Hum Reprod; 2016 Nov; 22(11):791-799. PubMed ID: 27604461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Telomere Recombination in Normal Mammalian Cells].
    Zhdanova NS; Rubtsov NB
    Genetika; 2016 Jan; 52(1):14-23. PubMed ID: 27183789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alternative lengthening of telomeres: mechanism and the pathogenesis of cancer.
    Mori JO; Keegan J; Flynn RL; Heaphy CM
    J Clin Pathol; 2024 Jan; 77(2):82-86. PubMed ID: 37890990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional Loss of
    Graham MK; Kim J; Da J; Brosnan-Cashman JA; Rizzo A; Baena Del Valle JA; Chia L; Rubenstein M; Davis C; Zheng Q; Cope L; Considine M; Haffner MC; De Marzo AM; Meeker AK; Heaphy CM
    Mol Cancer Res; 2019 Dec; 17(12):2480-2491. PubMed ID: 31611308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Life and cancer without telomerase: ALT and other strategies for making sure ends (don't) meet.
    Apte MS; Cooper JP
    Crit Rev Biochem Mol Biol; 2017 Feb; 52(1):57-73. PubMed ID: 27892716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-Molecule Telomere Assay via Optical Mapping (SMTA-OM) Can Potentially Define the ALT Positivity of Cancer.
    Raseley K; Jinwala Z; Zhang D; Xiao M
    Genes (Basel); 2023 Jun; 14(6):. PubMed ID: 37372458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of the alternative lengthening of telomeres pathway by trapping of proteins on DNA.
    Rose AM; Goncalves T; Cunniffe S; Geiller HEB; Kent T; Shepherd S; Ratnaweera M; O'Sullivan RJ; Gibbons RJ; Clynes D
    Nucleic Acids Res; 2023 Jul; 51(13):6509-6527. PubMed ID: 36940725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.